Walleye Capital LLC Has $270,000 Stake in NewAmsterdam Pharma (NASDAQ:NAMS)

Walleye Capital LLC reduced its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 77.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,506 shares of the company's stock after selling 36,441 shares during the quarter. Walleye Capital LLC's holdings in NewAmsterdam Pharma were worth $270,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in NAMS. National Bank of Canada FI acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $80,000. Barclays PLC raised its position in shares of NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma during the fourth quarter worth $154,000. Finally, HB Wealth Management LLC bought a new position in NewAmsterdam Pharma during the fourth quarter worth $224,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This trade represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 19.50% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank raised their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Finally, UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Trading Up 3.9 %

NewAmsterdam Pharma stock traded up $0.74 during midday trading on Thursday, reaching $19.87. 190,236 shares of the stock traded hands, compared to its average volume of 596,349. The firm has a fifty day moving average price of $19.58 and a two-hundred day moving average price of $21.21. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -7.66 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. Analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.